Download PDF
Dtsch Med Wochenschr 2017; 142(01): 17-23
DOI: 10.1055/s-0042-109195
Dossier
© Georg Thieme Verlag KG Stuttgart · New York

Aktuelle Therapieansätze der Sarkoidose

Current Therapeutic Approaches to Sarcoidosis
Carmen Pizarro
,
Dirk Skowasch
,
Christian Grohé
Further Information

Publication History

Publication Date:
05 January 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Sarcoidosis represents a non-caseating, granulomatous disorder of unknown aetiology whose clinical manifestation is heterogeneous and frequently multisystemic. The portion of patients needing systemic treatment varies: though many patients may undergo spontaneous remission, organ-threatening courses demand systemic therapy. Corticosteroids are the first-line treatment option; however, disease´s progression and/or major corticosteroid side effects may require second- and third-line therapeutics. A current stepwise therapeutic algorithm to sarcoidosis that characterizes additive and alternative therapeutic agents is given in the following review.

Die Sarkoidose ist eine Multisystemerkrankung mit heterogenem Erscheinungsbild. Die Indikation zur Therapie ist abhängig von der Art und dem Schweregrad der Organbeteiligung: Einerseits gibt es hohe Spontanremissionsraten, andererseits erzwingen Organschäden eine systemische Therapie. Einen aktuellen Überblick über die verfügbaren Substanzen im Therapiealgorithmus der Sarkoidose gibt der folgende Beitrag.

Schlüsselwörter

Sarkoidose - Kortikosteroide - Antimetabolite - Tumor-Nekrose-Faktor α-Blocker

Key words

sarcoidosis - corticosteroids - antimetabolites - tumor necrosis factor α-inhibitors
 

  • Literatur

  • 1 Valeyre D. Prasse A. Nunes H. et al. Sarcoidosis. Lancet 2014; 383: 1155-1167
    CrossrefPubMedGoogle Scholar
  • 2 Thomas KW. Hunninghake GW. Sarcoidosis. JAMA 2003; 289: 3300-3303
    CrossrefPubMedGoogle Scholar
  • 3 Baughman RP. Teirstein AS. Judson MA. et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164: 1885-1889
    CrossrefPubMedGoogle Scholar
  • 4 Drent M. Lower EE. De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40: 255-263
    CrossrefPubMedGoogle Scholar
  • 5 Baughman RP. Judson MA. Teirstein A. et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99: 307-315
    CrossrefPubMedGoogle Scholar
  • 6 Iannuzzi MC. Rybicki BA. Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357: 2153-2165
    CrossrefPubMedGoogle Scholar
  • 7 Judson MA. Corticosteroids in Sarcoidosis. Rheum Dis Clin North Am 2016; 42: 119-135
    CrossrefPubMedGoogle Scholar
  • 8 Schutt AC. Bullington WM. Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104: 717-723
    CrossrefPubMedGoogle Scholar
  • 9 Stern BJ. Neurological complications of sarcoidosis. Curr Opin Neurol 2004; 17: 311-316
    CrossrefPubMedGoogle Scholar
  • 10 Sweiss NJ. Lower EE. Korsten P. et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2011; 13: 265-272
    CrossrefPubMedGoogle Scholar
  • 11 Pietinalho A. Tukiainen P. Haahtela T. et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116: 424-431
    CrossrefPubMedGoogle Scholar
  • 12 Baughman RP. Iannuzzi MC. Lower EE. et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204
    PubMedGoogle Scholar
  • 13 du Bois RM. Greenhalgh PM. Southcott AM. et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-1350
    CrossrefPubMedGoogle Scholar
  • 14 Vorselaars AD. Wuyts WA. Vorselaars VM. et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013; 144: 805-812
    CrossrefPubMedGoogle Scholar
  • 15 Baughman RP. Winget DB. Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66
    PubMedGoogle Scholar
  • 16 Lacher MJ. Spontaneous remission or response to methotrexate in sarcoidosis. Ann Intern Med 1968; 69: 1247-1248
    CrossrefPubMedGoogle Scholar
  • 17 Agbogu BN. Stern BJ. Sewell C. et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995; 52: 875-879
    CrossrefPubMedGoogle Scholar
  • 18 Lower EE. Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155: 846-851
    CrossrefPubMedGoogle Scholar
  • 19 Baughman RP. Costabel U. du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548
    CrossrefPubMedGoogle Scholar
  • 20 Baughman RP. Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med 2015; 3: 813-822
    CrossrefPubMedGoogle Scholar
  • 21 Osiri M. Shea B. Robinson V. et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182-1190
    PubMedGoogle Scholar
  • 22 Baughman RP. Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48
    PubMedGoogle Scholar
  • 23 Sahoo DH. Bandyopadhyay D. Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38: 1145-1150
    CrossrefPubMedGoogle Scholar
  • 24 Galor A. Jabs DA. Leder HA. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-1832
    CrossrefPubMedGoogle Scholar
  • 25 Baughman RP. Drent M. Kavuru M. et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802
    CrossrefPubMedGoogle Scholar
  • 26 Rossman MD. Newman LS. Baughman RP. et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 201-208
    PubMedGoogle Scholar
  • 27 Vorselaars AD. Crommelin HA. Deneer VH. et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 2015; 46: 175-185
    CrossrefPubMedGoogle Scholar
  • 28 Judson MA. Baughman RP. Costabel U. et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196
    CrossrefPubMedGoogle Scholar
  • 29 Sweiss NJ. Noth I. Mirsaeidi M. et al. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 46-54
    PubMedGoogle Scholar
  • 30 Pariser RJ. Paul J. Hirano S. et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68: 765-773
    CrossrefPubMedGoogle Scholar
  • 31 Erckens RJ. Mostard RL. Wijnen PA. et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 713-720
    CrossrefPubMedGoogle Scholar
  • 32 Utz JP. Limper AH. Kalra S. et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-185
    CrossrefPubMedGoogle Scholar
  • 33 Baughman RP. Lower EE. Bradley DA. et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-1067
    CrossrefPubMedGoogle Scholar
  • 34 Judson MA. Baughman RP. Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44: 1296-1307
    CrossrefPubMedGoogle Scholar
  • 35 Daïen CI. Monnier A. Claudepierre P. et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009; 48: 883-886
    CrossrefPubMedGoogle Scholar
  • 36 Drake WP. Oswald-Richter K. Richmond BW. et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol 2013; 149: 1040-1049
    CrossrefPubMedGoogle Scholar
  • 37 Drake W. Richmond BW. Oswald-Richter K. et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 201-211
    PubMedGoogle Scholar
  • 38 Drake WP. Dhason MS. Nadaf M. et al. Cellular recognition of Mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis. Infect Immun 2007; 75: 527-530
    CrossrefPubMedGoogle Scholar
  • 39 Sweiss NJ. Lower EE. Mirsaeidi M. et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 2014; 43: 1525-1528
    CrossrefPubMedGoogle Scholar
  • 40 Lower EE. Baughman RP. Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618
    PubMedGoogle Scholar
  • 41 Baughman RP. Barney JB. O'Hare L. et al. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med 2016; 110: 66-72
    CrossrefPubMedGoogle Scholar